(EMAILWIRE.COM, April 10, 2019 ) The global oligonucleotide synthesis market is valued at USD 1.33 Billion in 2016 and is projected to reach USD 2.46 Billion by 2022, at a CAGR of 10.9%.

The oligonucleotide synthesis market is highly competitive with the presence of several small and big players. Prominent players in the market include Integrated DNA Technologies (IDT) (US), Sigma-Aldrich Corporation (US) (part of Merck KGaA), Eurogentec (Belgium), Eurofins Genomics (Germany), Agilent Technologies (US), Thermo Fisher Scientific (US)

Download FREE Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=200829350

The growth of this market is mainly driven by the increasing research activities in the pharma and biotech sectors and the rising demand for innovative diagnostic and therapeutic techniques.

Target Audience for this Report:
-Life science instrumentation and reagent companies
-Pharmaceutical and biotechnology companies
-Hospitals and clinics
-Academic researchers and government research organizations
-Private research institutes
-Custom oligonucleotide service providers

In 2017, North America is expected to dominate the market followed by Europe. Asia Pacific is expected to grow at the highest CAGR during the forecast period. This can be attributed to factors such as the growing availability of synthesized oligos, along with an increase in R&D funding and activities in the APAC region.

Speak to Our Expert @ https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=200829350

The increasing focus of prominent players on APAC is also supporting market growth in the region. However, price erosion and a lack of regulations for therapeutic oligonucleotides could hinder the growth of this market to a certain extent.